Dr Mary Beth  Dorr,PhD, Clinical Director Merck & Co., Inc.

Dr Mary Beth Dorr,PhD, Clinical Director Merck & Co., Inc.

Dr. Mary Beth Dorr is the product development lead for ZINPLAVA (bezlotoxumab), a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects.She has an undergraduate pharmacy degree from the University of the Sciences’ Philadelphia College of Pharmacy and completed a clinical pharmacy residency at the Veteran's Administration Hospital in Philadelphia,completed her PhD in pharmaceutics with an emphasis on pharmacokinetics and drug metabolism at the University of North Carolina in Chapel Hill. She joined the pharmaceutical industry in 1988, and has devoted her career to the design and implementation of Phase 1 to 4 clinical trials, primarily for anti-infective products.Mary Beth has wide-ranging drug-development experience at several pharmaceutical companies,including Parke-Davis/Warner Lambert,Rhone-Poulenc Rorer/Aventis, Vicuron,Wyeth/Pfizer, where she worked in pharmacokinetics/drug metabolism, clinical research, project management,& global med.